Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
In: Lung Cancer, Jg. 190 (2024-04-01)
academicJournal
Zugriff:
Titel: |
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
|
---|---|
Autor/in / Beteiligte Person: | Hong, David S. ; Cappuzzo, Federico ; Chul Cho, Byoung ; Dowlati, Afshin ; Hussein, Maen ; Kim, Dong-Wan ; Percent, Ivor ; Christensen, James G. ; Morin, Josée ; Potvin, Diane ; Faltaos, Demiana ; Tassell, Vanessa ; Der-Torossian, Hirak ; Chao, Richard |
Link: | |
Zeitschrift: | Lung Cancer, Jg. 190 (2024-04-01) |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 0169-5002 (electronic) |
DOI: | 10.1016/j.lungcan.2024.107512 |
Sonstiges: |
|